- Home
- NBR vs CDNA Comparison
NBR vs CDNA Comparison
Compare NBR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBR | CDNA |
|---|---|---|
| Founded | 1952 | 1998 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 687.5M | 712.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NBR | CDNA |
|---|---|---|
| Price | $50.10 | $17.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $48.00 | $26.00 |
| AVG Volume (30 Days) | 379.1K | ★ 1.1M |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 14.43 | 1.22 |
| Revenue | ★ $3,116,983,000.00 | $357,998,000.00 |
| Revenue This Year | $9.24 | $12.73 |
| Revenue Next Year | $0.09 | $11.90 |
| P/E Ratio | ★ $3.50 | $14.14 |
| Revenue Growth | 6.52 | ★ 14.46 |
| 52 Week Low | $23.27 | $10.96 |
| 52 Week High | $74.14 | $26.37 |
Technical Indicators
Market Signals| Indicator | NBR | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.03 | 61.90 |
| Support Level | $44.93 | $17.11 |
| Resistance Level | $51.46 | $18.20 |
| Average True Range (ATR) | 2.47 | 0.75 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 77.54 | 81.61 |
Price Performance
Historical ComparisonAbout NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.